



Appl. No. 10/661,730
Atty. Docket No. 8717MC
Amdt. dated April 5, 2005
Reply to Office Action of March 15, 2005
Customer No. 27752

AMENDMENTS TO THE CLAIMS

1. (Previously presented) The compound 2-(4-fluorophenyl)-3-(2-phenoxy-pyrimidin-4-yl)-6,7-dihydro-5H-pyrazolo-[1,2-a]pyrazol-1-one, including all enantiomeric and diastereomeric forms and pharmaceutically acceptable salts thereof, said compound having the formula:




2. (Previously presented) A pharmaceutical composition comprising:
- a) an effective amount of the compound 2-(4-fluorophenyl)-3-(2-phenoxy-pyrimidin-4-yl)-6,7-dihydro-5H-pyrazolo-[1,2-a]pyrazol-1-one, including all enantiomeric and diastereomeric forms and pharmaceutically acceptable salts thereof, said compound having the formula:



- b) one or more pharmaceutically acceptable excipients.
3. (Previously presented) The compound 2-(4-fluorophenyl)-3-[2-(2-hydroxy-1,2-dimethylpropylamino)pyrimidin-4-yl]-6,7-dihydro-5H-pyrazolo[1,2-a]pyrazol-1-one, including all enantiomeric and diastereomeric forms and pharmaceutically acceptable salts thereof, said compound having the formula:


Appl. No. 10/661,730
 Atty. Docket No. 8717MC
 Amdt. dated April 5, 2005
 Reply to Office Action of March 15, 2005
 Customer No. 27752



4. (Currently amended)

A pharmaceutical composition comprising:

- a) an effective amount of the compound 2-(4-fluorophenyl)-3-[2-(2-hydroxy-1,2-dimethylpropylamino)pyrimidin-4-yl]-6,7-dihydro-5H-pyrazolo[1,2-a]pyrazol-1-one ~~2-(4-fluorophenyl)-3-(2-phenoxy-pyrimidin-4-yl)-6,7-dihydro-5H-pyrazolo[1,2-a]pyrazol-1-one~~, including all enantiomeric and diastereomeric forms and pharmaceutically acceptable salts thereof, said compound having the formula:



; and


- b) one or more pharmaceutically acceptable excipients.

5. (Currently amended)

A method for controlling the ~~osteoarthritis,~~ rheumatoid arthritis ~~and diabetes~~ in humans, said method comprising the step of administering to said humans a pharmaceutical composition comprising:

Appl. No. 10/661,730
 Atty. Docket No. 8717MC
 Amdt. dated April 5, 2005
 Reply to Office Action of March 15, 2005
 Customer No. 27752

- a) an effective amount of one or more bicyclic pyrazolones including all enantiomeric and diastereomeric forms and pharmaceutically acceptable salts thereof, said compound having the formula:



wherein R is:

- a) $-\text{O}[\text{CH}_2]_k\text{R}^3$; or
 b) $-\text{NR}^{4a}\text{R}^{4b}$;

R^3 is substituted or unsubstituted C_1 - C_4 alkyl, substituted or unsubstituted heterocyclic, substituted or unsubstituted hydrocarbyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl or alkylenearyl, substituted or unsubstituted heteroaryl or alkyleneheteroaryl; the index k is from 0 to 5;

R^{4a} and R^{4b} are each independently:

- a) hydrogen; or
 b) $-\text{C}(\text{R}^{5a}\text{R}^{5b})_m\text{R}^6$;

each R^{5a} and R^{5b} are independently hydrogen, or C_1 - C_4 linear, branched, or cyclic alkyl, and mixtures thereof; R^6 is hydrogen, $-\text{OR}^7$, $-\text{N}(\text{R}^7)_2$, $-\text{CO}_2\text{R}^7$, $-\text{CON}(\text{R}^7)_2$; substituted or unsubstituted C_1 - C_4 alkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl; R^7 is hydrogen, a water-soluble cation, C_1 - C_4 alkyl, or substituted or unsubstituted aryl; the index m is from 0 to 5;

R^1 is:

- a) substituted or unsubstituted aryl; or
 b) substituted or unsubstituted heteroaryl;

each R^2 unit is independently selected from the group consisting of:


Page 5 of 10

Appl. No. 10/661,730
 Atty. Docket No. 8717MC
 Amdt. dated April 5, 2005
 Reply to Office Action of March 15, 2005
 Customer No. 27752

- a) hydrogen;
 - b) $-(CH_2)_jO(CH_2)_nR^8$;
 - c) $-(CH_2)_jNR^{9a}R^{9b}$;
 - d) $-(CH_2)_jCO_2R^{10}$;
 - e) $-(CH_2)_jOCO_2R^{10}$
 - f) $-(CH_2)_jCON(R^{10})_2$;
 - g) $-(CH_2)_jOCON(R^{10})_2$;
 - h) two R^2 units can be taken together to form a carbonyl unit;
 - i) and mixtures thereof;
- R^8 , R^{9a} , R^{9b} , and R^{10} are each independently hydrogen, C_1 - C_4 alkyl, and mixtures thereof; R^{9a} and R^{9b} can be taken together to form a carbocyclic or heterocyclic ring comprising from 3 to 7 atoms; two R^{10} units can be taken together to form a carbocyclic or heterocyclic ring comprising from 3 to 7 atoms; j is an index from 0 to 5, n is an index from 0 to 5; Z is O, S, NR^{11} , or NOR^{11} ; R^{11} is hydrogen or C_1 - C_4 alkyl; and
- b) one or more pharmaceutically acceptable excipients.

6. (Currently amended) A method for controlling the ~~osteoarthritis,~~ ~~rheumatoid arthritis and diabetes~~ in humans, said method comprising the step of administering to said humans a pharmaceutical composition comprising:
- a) an effective amount of the compound 2-(4-fluorophenyl)-3-(2-phenoxy-pyrimidin-4-yl)-6,7-dihydro-5H-pyrazolo-[1,2-a]pyrazol-1-one, including all enantiomeric and diastereomeric forms and pharmaceutically acceptable salts thereof, said compound having the formula:

Appl. No. 10/661,730
 Atty. Docket No. 8717MC
 Amdt. dated April 5, 2005
 Reply to Office Action of March 15, 2005
 Customer No. 27752




b) one or more pharmaceutically acceptable excipients.

7. (Currently amended)

A method for controlling the ~~osteoarthritis,~~
~~rheumatoid arthritis and diabetes~~ in humans, said method comprising the step of
 administering to said humans a pharmaceutical composition comprising:

a) an effective amount of the compound 2-(4-fluorophenyl)-3-[2-(2-hydroxy-1,2-dimethylpropylamino)pyrimidin-4-yl]-6,7-dihydro-5H-pyrazolo[1,2-a]pyrazol-1-one, including all enantiomeric and diastereomeric forms and pharmaceutically acceptable salts thereof, said compound having the formula:



b) one or more pharmaceutically acceptable excipients.

8. (Currently amended)


A method for controlling the level of one or more
 inflammation inducing cytokines selected from the group consisting of,
 interleukin-1 (IL-1), Tumor Necrosis Factor- α (TNF- α), interleukin-6 (IL-6), and

Appl. No. 10/661,730
Atty. Docket No. 8717MC
Amdt. dated April 5, 2005
Reply to Office Action of March 15, 2005
Customer No. 27752


interleukin-8 (IL-8), ~~thereby controlling, mediating, or abating disease states affected by the level of extracellular inflammatory cytokines in humans~~, said method comprising the step of administering to said humans a pharmaceutical composition comprising:

- a) an effective amount of one or more bicyclic pyrazolones including all enantiomeric and diastereomeric forms and pharmaceutically acceptable salts thereof, said compound selected from bicyclic pyrazolones having the formula:

i)



ii)



iii) mixtures thereof; and

- b) one or more pharmaceutically acceptable excipients.